Drugs that contain Icatibant Acetate
1. Firazyr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5648333 | TAKEDA PHARMS USA | Peptides having bradykinin antagonist action |
Jul, 2014
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-14) | Aug 25, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 25, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 25, 2018 |
NCE-1 date: 26 August, 2015
Market Authorisation Date: 25 August, 2011
Treatment: Treatment of pathological state by antagonizing bradykinin receptor including treatment of acute attacks of hereditary angioedema (hae)
Dosage: INJECTABLE;SUBCUTANEOUS
How can I launch a generic of FIRAZYR before it's drug patent expiration?
More Information on Dosage
FIRAZYR family patents
